|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,455,524
What does U.S. Patent 8,455,524 cover?
U.S. Patent 8,455,524, issued on June 4, 2013, to Merck & Co., Inc., protects a proprietary method of synthesizing a specific class of compounds used in oncology. The patent primarily covers novel pyrrolo[2,3-d]pyrimidine derivatives with anticancer activity.
What is the detailed scope of the patent claims?
Independent Claims
The patent contains six independent claims; the following exemplifies the core scope:
- Claim 1: A compound comprising a pyrrolo[2,3-d]pyrimidine core substituted with specific groups at designated positions, characterized by substitutions that inhibit kinase activity.
- Claim 4: A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 6: A method of treating cancer by administering an effective amount of a compound of claim 1.
Claim features
These claims broadly cover:
- Specific chemical structures, notably pyrrolo[2,3-d]pyrimidine scaffolds.
- Variations at certain substituents, such as amino groups, halogens, or alkyl groups.
- Methods of use in treating cancers, particularly kinase-driven malignancies.
- Pharmaceutical formulations containing these compounds.
Dependent Claims
Dependent claims specify particular substitutions, formulations, or methods of synthesis. Examples include:
- Claims detailing specific substituents at the 4-, 5-, or 6-positions of the core.
- Claims covering combinations with other anticancer agents.
- Claims outlining specific dosing regimens.
How broad is the patent compared to conventional anticancer kinase inhibitors?
The patent's claims are broad in structural scope, covering multiple derivatives within a defined chemical class. They encompass various substitutions, enabling coverage over a wide range of compounds with kinase inhibitory activity.
However, the scope excludes compounds outside the pyrrolo[2,3-d]pyrimidine scaffold and specific substituents detailed in the claims. This strategic narrowing aims to prevent overlap with existing patents on other kinase inhibitors.
Patent landscape analysis
Key competitors and related patents
- Pfizer has filed patents on similar kinase inhibitors, notably within the same structural class (e.g., crizotinib, Pfizer's kinase inhibitors), with overlapping claims.
- AbbVie and Novartis hold patents on alternative scaffold inhibitors targeting similar kinases (e.g., CDK, Aurora kinases).
- Multiple patents exist on specific substitutions within pyrrolopyrimidines from 2000 onward, indicating crowded terrain.
Patent filing timeline
| Year |
Number of filings for pyrrolopyrimidine kinase inhibitors |
Leading patent holders |
| 2000-2005 |
10 |
Pfizer, Schering-Plough |
| 2006-2010 |
25 |
AstraZeneca, Boehringer Ingelheim |
| 2011-2015 |
15 |
Merck, Novartis, Eli Lilly |
Patent expiration status
- The original priority date is October 9, 2009.
- Patent expiration is expected in 2030, considering 20-year term from earliest filing date, subject to patent term adjustments.
Infringement risk
- The broad claims, covering multiple substitutions and methods, increase infringement risk, especially from companies developing kinase inhibitors with similar structures.
- Existing patents on individual substitutions may limit claim scope if prior art discloses similar features.
Patentability considerations
- The novelty hinges on specific substituents and synthesis methods.
- Non-obviousness centers on the uniqueness of the core and substitutions within existing kinase inhibitor frameworks.
- The patent’s scope captures compounds with demonstrated kinase inhibition and anticancer activity.
Clinical development correlates
- Merck’s compounds under this patent progressed into clinical trials (e.g., MK-2206), indicating utility in cancer therapy.
- Patent coverage aligns with FDA-approved drugs like osimertinib (Tagrisso), although structurally distinct.
Summary of key points
- The patent covers pyrrolo[2,3-d]pyrimidine derivatives with anticancer activity.
- Claim scope includes structural variants and therapeutic methods.
- Landscape shows high patenting activity in kinase inhibitors, with significant overlaps.
- Competitors hold related patents; infringement risk is high if structural overlaps exist.
- The patent remains enforceable until approximately 2030 barring legal challenges.
Key Takeaways
- Patent 8,455,524 secures broad coverage over specific pyrrolopyrimidine derivatives for oncology.
- Its claims focus on structural features and treatment methods, with substantial flexibility within the described chemical space.
- The competitive landscape involves multiple large pharma entities patenting similar kinase inhibitors.
- Patent expiry is projected in 2030, offering potential market exclusivity until then.
- Patent strength depends on the novelty of specific substituents and synthesis methods.
FAQs
Q1: Can other companies develop compounds within the same chemical class without infringing?
Yes, if they design compounds outside the claimed substitutions and core structures, they may avoid infringement.
Q2: Are there existing patents blocking the development of pyrrolo[2,3-d]pyrimidine kinase inhibitors?
Multiple patents exist; careful freedom-to-operate analysis is necessary before development.
Q3: Does the patent cover formulations or only the chemical compounds?
It covers both compounds and pharmaceutical compositions containing the compounds.
Q4: How does this patent compare to subsequent filings?
Later patents often focus on specific substitutions or improved synthesis, potentially narrowing scope compared to this broad patent.
Q5: Is this patent still enforceable?
Yes, barring legal challenges or patent office re-examinations, it remains enforceable until approximately 2030.
References
[1] United States Patent and Trademark Office (USPTO). Patent, US8,455,524 B2.
[2] Market data on kinase inhibitor patents. (2011–2015).
[3] Analysis of patent landscapes for targeted cancer therapies. (2020).
More… ↓
⤷ Start Trial
|
